Clinical Trials
55 trialsNCT03899155 2026-05-27
Pan Tumor Rollover Study
Bristol-Myers Squibb
Phase 2 Recruiting
NCT04958239 2026-05-27
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT06551142 2026-05-22
PanTumor-101
GlaxoSmithKline
Phase 1 Recruiting
NCT03030378 2026-05-19
Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04130542 2026-05-19
Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy
Lyvgen Biopharma Holdings Limited
Phase 1 Completed
NCT07247110 2026-05-14
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
Merck Sharp & Dohme LLC
Phase 1 Recruiting
NCT06697301 2026-05-08
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Eikon Therapeutics
Phase 2/3 Recruiting
NCT05365581 2026-05-05
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
Astellas Pharma Inc
Phase 1 Recruiting
NCT03752333 2026-05-04
CUPem
Imperial College London
Phase 2 Completed
NCT05378425 2026-04-30
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
Nectin Therapeutics Ltd
Phase 1 Active not recruiting
NCT06901531 2026-04-29
LUCERNA
Astellas Pharma Inc
Phase 3 Recruiting
NCT03768063 2026-04-28
IMbrella B
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05349890 2026-04-24
Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
Providence Health & Services
Phase 1 Active not recruiting
NCT06669572 2026-04-15
Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment
University of Chicago
Phase 2 Recruiting
NCT05382559 2026-04-14
A Study of ASP3082 in Adults With Advanced Solid Tumors
Astellas Pharma Inc
Phase 1 Recruiting
NCT04520711 2026-04-13
Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
Providence Health & Services
Phase 1 Active not recruiting
NCT04799054 2026-04-13
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
Ascendis Pharma A/S
Phase 1/2 Terminated
NCT04847466 2026-04-08
Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT06031233 2026-03-30
MINUTE
Isala
Phase 4 Recruiting
NCT06188208 2026-03-30
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors
Vividion Therapeutics, Inc.
Phase 1 Terminated
NCT03568058 2026-03-24
Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers
University of California, San Diego
Phase 1 Completed
NCT05027633 2026-03-20
Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04443088 2026-03-18
KEYNOTE-E12
Shenzhen Ionova Life Sciences Co., Ltd.
Phase 1 Recruiting
NCT03833167 2026-03-10
KEYNOTE-630
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03976362 2026-02-25
KEYLYNK-008
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04150900 2026-02-19
1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck
University of Maryland, Baltimore
Phase 2 Active not recruiting
NCT07404332 2026-02-11
5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors
University of Iowa
Phase 1 Not yet recruiting
NCT04260529 2026-01-29
CICILIA
Cytovation AS
Phase 1/2 Completed
NCT05273554 2026-01-12
A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04795661 2026-01-07
IMHOTEP
Centre Leon Berard
Phase 2 Active not recruiting
NCT02560636 2026-01-06
PLUMMB
Royal Marsden NHS Foundation Trust
Phase 1 Active not recruiting
NCT07197827 2025-12-24
A Study of YL242 in Subjects With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2 Recruiting
NCT05270213 2025-12-19
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
Riboscience, LLC.
Phase 1 Recruiting
NCT05165433 2025-12-16
FORTIFY
Akamis Bio
Phase 1 Completed
NCT06108050 2025-12-16
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
Jazz Pharmaceuticals
Phase 1 Recruiting
NCT04009681 2025-12-15
HAMMER
Synthorx, Inc, a Sanofi company
Phase 1/2 Terminated
NCT06724042 2025-12-10
Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors
InSilico Medicine Hong Kong Limited
Phase 1 Not yet recruiting
NCT05338658 2025-12-09
Study of PAT in Patients With Solid Tumor Cancers
Masonic Cancer Center, University of Minnesota
Phase 1 Recruiting
NCT07021898 2025-12-03
BOREALIS-1
Erasca, Inc.
Phase 1 Recruiting
NCT05383170 2025-11-28
Catalyst
Cytovation AS
Phase 1/2 Completed
NCT03486301 2025-11-12
EIK1001
Eikon Therapeutics
Phase 1 Completed
NCT04840394 2025-11-12
Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Eikon Therapeutics
Phase 1 Completed
NCT06246110 2025-11-12
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
Eikon Therapeutics
Phase 2 Recruiting
NCT02959437 2025-10-21
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
Incyte Corporation
Phase 1/2 Terminated
NCT05514444 2025-10-09
MK-4464-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT03564691 2025-10-07
MK-4830-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT05501821 2025-09-25
Study of KBA1412 in Participants With Advanced Solid Malignant Tumors
Kling Biotherapeutics B.V.
Phase 1 Completed
NCT06983743 2025-09-11
AURORAS-1
Erasca, Inc.
Phase 1 Recruiting
NCT06831136 2025-09-10
PANCARDINAL-2
The University of Texas Health Science Center, Houston
Phase 2 Recruiting
NCT07018570 2025-08-26
An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma
National Cancer Center Hospital East
Phase 2 Recruiting